Published in Am J Clin Oncol on October 01, 2013
Metastasis of ciliary body melanoma to the contralateral eye: a case report and review of uveal melanoma literature. Case Rep Oncol Med (2015) 0.75
Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc (2015) 0.75
Malignant perivascular melanoma mimicking primary central nervous system vasculitis. J Neurol (2012) 0.75
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 3.14
Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci (2003) 2.58
Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol (2001) 2.52
Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg (1990) 2.27
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05
Prognosis and treatment of disseminated uveal melanoma. Cancer (1993) 1.98
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol (2006) 1.93
Survival of patients with metastases from uveal melanoma. Ophthalmology (1991) 1.80
Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Variates of survival in metastatic uveal melanoma. J Clin Oncol (2005) 1.45
Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci (2002) 1.33
Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol (2004) 1.30
The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg (1989) 1.21
Brain metastasis from melanoma. J Neurooncol (1983) 1.21
Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol (1993) 1.18
Late recurrence of cutaneous melanoma. Arch Surg (1983) 1.16
Late relapse from cutaneous stage I malignant melanoma. Arch Surg (1985) 1.16
Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin (2006) 1.15
Late metastases (beyond ten years) of cutaneous malignant melanoma. Literature review and case report. J Am Acad Dermatol (1986) 1.08
Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res (2010) 0.96
Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more. J Eur Acad Dermatol Venereol (2010) 0.92
MET oncogene inhibition as a potential target of therapy for uveal melanomas. Invest Ophthalmol Vis Sci (2010) 0.91
Prognosis in metastatic choroidal melanoma. South Med J (1981) 0.90
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci (2005) 0.89
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer (2002) 0.85
Expression of epidermal growth factor receptor: risk factor in uveal melanoma. Invest Ophthalmol Vis Sci (2000) 0.83
Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. Invest Ophthalmol Vis Sci (1998) 0.83
Expression of insulin-like growth factor receptor (IGF-1R), c-Fos, and c-Jun in uveal melanoma: an immunohistochemical study. Curr Eye Res (2006) 0.78
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol (2002) 1.65
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood (2012) 1.58
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res (2012) 1.55
Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer (2004) 1.47
Meta-analyses of colorectal cancer risk factors. Cancer Causes Control (2013) 1.42
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother (2009) 1.36
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res (2008) 1.33
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer (2012) 1.32
Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer (2004) 1.30
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet (2012) 1.07
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Clin Cancer Res (2012) 1.05
Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2012) 1.03
Tumor volume as a prognostic factor for sarcomatosis. Cancer (2002) 1.02
Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2013) 0.99
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol (2007) 0.99
PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res (2008) 0.98
Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg (2007) 0.98
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest (2009) 0.97
Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Obstet Gynecol (2010) 0.97
What is the best reference RNA? And other questions regarding the design and analysis of two-color microarray experiments. OMICS (2007) 0.95
A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer (2005) 0.95
Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck (2008) 0.95
GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res (2010) 0.94
Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res (2008) 0.93
Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2013) 0.92
The dominant negative thyroid hormone receptor beta-mutant {Delta}337T alters PPAR{alpha} signaling in heart. Am J Physiol Endocrinol Metab (2006) 0.91
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol (2010) 0.91
Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer (2007) 0.90
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res (2008) 0.90
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol (2010) 0.90
Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol (2012) 0.89
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res (2010) 0.89
Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys (2002) 0.88
A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer (2012) 0.87
Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol (2011) 0.86
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res (2012) 0.86
Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics (2011) 0.86
Learning curves in classification with microarray data. Semin Oncol (2010) 0.83
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res (2009) 0.83
The role of taxanes in the treatment of metastatic melanoma. Melanoma Res (2004) 0.83
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res (2009) 0.83
Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib. J Clin Aesthet Dermatol (2013) 0.83
Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol (2010) 0.83
Latest developments in the biology and management of uveal melanoma. Curr Oncol Rep (2013) 0.82
A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res (2008) 0.82
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. Melanoma Res (2010) 0.82
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med (2010) 0.82
A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res (2011) 0.82
Case of vemurafenib-induced Sweet's syndrome. J Dermatol (2014) 0.81
Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res (2011) 0.80
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer (2012) 0.80
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res (2011) 0.79
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs (2015) 0.79
Challenges of chemosensitivity testing. Clin Cancer Res (2006) 0.79
Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest (2011) 0.79
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant (2007) 0.78
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol (2012) 0.78
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res (2014) 0.78
FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am J Physiol Gastrointest Liver Physiol (2013) 0.78
Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease. J Invest Dermatol (2013) 0.78
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol (2008) 0.78
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs (2002) 0.78
Hormonal suppression restores fertility in irradiated mice from both endogenous and donor-derived stem spermatogonia. Toxicol Sci (2010) 0.78
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer (2009) 0.77
Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells. Cell Cycle (2014) 0.77
Neonatal sporotrichosis. Pediatr Dermatol (2009) 0.76
Surveillance options for patients with uveal melanoma following definitive management. Am Soc Clin Oncol Educ Book (2013) 0.76
Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma. Melanoma Res (2014) 0.75
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res (2016) 0.75
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother (2013) 0.75
Functional analysis of limb transcriptional enhancers in the mouse. Evol Dev (2014) 0.75